Crimson BioPharm Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$400K
- Investors
-
3
Crimson BioPharm General Information
Description
Operator of a biotechnological company intended to develop oral treatments for glioblastoma. The company is currently operating in stealth mode.
Contact Information
Corporate Office
- 9 Bradford Terrace
- Unit 6
- Brookline, MA 02446
- United States
Corporate Office
- 9 Bradford Terrace
- Unit 6
- Brookline, MA 02446
- United States
Crimson BioPharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Grant | 30-Apr-2024 | $400K | Completed | Stealth | ||
| 1. Seed Round | 04-Oct-2019 | Completed | Stealth |
Crimson BioPharm Patents
Crimson BioPharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4367116-A1 | Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof | Pending | 07-Jul-2021 | ||
| EP-4367116-A4 | Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof | Pending | 07-Jul-2021 | ||
| US-20240239796-A1 | Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof | Pending | 07-Jul-2021 | ||
| WO-2023283206-A1 | Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof | Inactive | 07-Jul-2021 | ||
| AU-2022297453-A1 | (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors | Inactive | 22-Jun-2021 | A61K31/506 |
Crimson BioPharm Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| EQRx | Corporation | Minority | ||
| Third Rock Ventures | Venture Capital | Minority |
Crimson BioPharm FAQs
-
When was Crimson BioPharm founded?
Crimson BioPharm was founded in 2018.
-
Where is Crimson BioPharm headquartered?
Crimson BioPharm is headquartered in Brookline, MA.
-
What industry is Crimson BioPharm in?
Crimson BioPharm’s primary industry is Pharmaceuticals.
-
Is Crimson BioPharm a private or public company?
Crimson BioPharm is a Private company.
-
What is Crimson BioPharm’s current revenue?
The current revenue for Crimson BioPharm is .
-
How much funding has Crimson BioPharm raised over time?
Crimson BioPharm has raised $1M.
-
Who are Crimson BioPharm’s investors?
National Institutes of Health, EQRx, and Third Rock Ventures have invested in Crimson BioPharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process